RxDoctor Payments Data

Holly Keyt, MD

Critical Care Medicine · San Antonio, TXNPI 1699902965

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Insmed, Inc. accounts for 91.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $10,641 and has fallen 96.6% since, to $358 in 2025. Among critical care medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,137in general payments, 2019–2025

Across 75 payments — averaging $188.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$13K
  • Vertex$263
  • Gilead$223
  • Chiesi USA, Inc.$151
  • Astellas Pharma US Inc$145
  • Olympus America Inc.$135
  • plus $330 from 8 others
$30,424in research payments, 2019–2025

Across 4 payments — averaging $7606.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$30K

What the payments were for

  • Consulting fees$2,70019%
  • Speaking & faculty fees$8,32559%
  • Travel & lodging$1,2028%
  • Food & beverage$1,81713%
  • Education$210%
  • Gifts$711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,137 in reported general payments places this provider in the 90th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$17,576
Medicare patients
53
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrevymisLetermovir28$187,642
Posaconazole16$20,292
Atovaquone27$13,056
Valganciclovir Hcl45$11,414
Tacrolimus63$5,233
Amphotericin B Liposome12$2,535
Prednisone27$596
Acyclovir24$214
Pantoprazole Sodium41$198
Famotidine14$188
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim36$162
Rosuvastatin Calcium16$55
Metoprolol Tartrate14$30

Paid to pharmacies, not to this prescriber.

Other critical care medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →